Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - Concepedia

Concepedia

Publication | Open Access

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

DOI Full Paper Access

138

Citations

45

References

2019

Year

Komal Jhaveri, X.V. Wang, Vicky Makker, Shiuh‐Wen Luoh, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Robert J. Gray, S. Li, Lisa M. McShane,

Annals of Oncology

References

	Year	Citations

Page 1